non-opioid painkiller

News

Latigo raises $150m for non-opioid painkiller push

Latigo has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, raising $150 million in a Series B.

News

Vertex bags FDA okay for its non-opioid pain drug

Vertex gets FDA approval for its non-opioid pain drug suzetrigine, the first new class of pain medicine in the US in more than 20 years.

News

Sun Pharma, Taro Pharma, and Antibe Therapeutics logos

Sun Pharma unit poised to buy Canadian biotech Antibe

Sun Pharma's Taro unit has made a bid to acquire Canadian biotech Antibe, a developer of drugs for pain and inflammation.

News

Silhouette graphic of a main with spinal pain in the lumbar region

Vertex weakens after neuropathic pain trial reads out

A trial of Vertex's suzetrigine in neuropathic back pain met its primary objective, but shares in the company fell as investors reacted to the data.

News

Novo Holdings leads $100m round for novel painkiller biotech

SiteOne Therapeutics has completed a $100 million third-round financing that will support clinical trials of its non-opioid painkiller.

R&D